Life first and science respect: A commentary on current status and expectations of China's lung transplantation
Q4 Medicine
Bo Wu, Chun-xiao Hu, Xiao-shan Li, Jingyu Chen
{"title":"Life first and science respect: A commentary on current status and expectations of China's lung transplantation","authors":"Bo Wu, Chun-xiao Hu, Xiao-shan Li, Jingyu Chen","doi":"10.14188/j.1671⁃8852.2021.6001","DOIUrl":null,"url":null,"abstract":"Lung transplantation is the only effective method for the treatment of end-stage lung diseases. Lung transplantation has achieved rapid development in the world. At present, about 4 000 cases are carried out every year, and the long-term survival rate has gradually improved. With a high incidence of lung disease in China, at least ten thousand patients with respiratory failure need lung transplantation every year. In 2020, 29 lung transplantation centers in China has carried out more than 500 cases of lung transplantation. Idiopathic pulmonary interstitial fibrosis, chronic obstructive pulmonary disease, secondary pulmonary interstitial fibrosis and pneumoconiosis were the main primary diseases in lung transplantation recipients in China. Single-lung transplantation accounted for 57.6% and double-lung transplantation accounted for 42.4%, respectively. Peri-operation (<30 days), one-year, and three-year survival rates were 78.5%, 64.5% and 48.9%, respectively for double-lung transplant. The corresponding survival rates for single-lung transplant recipients were 83.0%, 69.9% and 46.8%, respectively. The Renmin Hospital of Wuhan University completed the first case of COVID-19 lung transplantation operation in Hubei Province in 2020, and the patients recovered and discharged successfully after the operation. Although China has made great progress in lung transplantation, it is still necessary to realize that the multi-disciplinary team cooperation mode and data registration management still need to be further strengthened, in order to provide more clinical guidelines and expert consensus and make the steady development and improvement of each lung transplantation center. The lung transplantation in China will be gradually promoted to the center of the organ transplantation stage in the world. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.","PeriodicalId":35402,"journal":{"name":"武汉大学学报(医学版)","volume":"42 1","pages":"517-519"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"武汉大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14188/j.1671⁃8852.2021.6001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
Abstract
Lung transplantation is the only effective method for the treatment of end-stage lung diseases. Lung transplantation has achieved rapid development in the world. At present, about 4 000 cases are carried out every year, and the long-term survival rate has gradually improved. With a high incidence of lung disease in China, at least ten thousand patients with respiratory failure need lung transplantation every year. In 2020, 29 lung transplantation centers in China has carried out more than 500 cases of lung transplantation. Idiopathic pulmonary interstitial fibrosis, chronic obstructive pulmonary disease, secondary pulmonary interstitial fibrosis and pneumoconiosis were the main primary diseases in lung transplantation recipients in China. Single-lung transplantation accounted for 57.6% and double-lung transplantation accounted for 42.4%, respectively. Peri-operation (<30 days), one-year, and three-year survival rates were 78.5%, 64.5% and 48.9%, respectively for double-lung transplant. The corresponding survival rates for single-lung transplant recipients were 83.0%, 69.9% and 46.8%, respectively. The Renmin Hospital of Wuhan University completed the first case of COVID-19 lung transplantation operation in Hubei Province in 2020, and the patients recovered and discharged successfully after the operation. Although China has made great progress in lung transplantation, it is still necessary to realize that the multi-disciplinary team cooperation mode and data registration management still need to be further strengthened, in order to provide more clinical guidelines and expert consensus and make the steady development and improvement of each lung transplantation center. The lung transplantation in China will be gradually promoted to the center of the organ transplantation stage in the world. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.
生命至上与科学尊重:中国肺移植现状与展望述评
肺移植是治疗终末期肺部疾病的唯一有效方法。肺移植在世界范围内取得了快速发展。目前每年开展约4000例,长期生存率逐步提高。中国肺病发病率高,每年至少有1万例呼吸衰竭患者需要肺移植。2020年,全国29家肺移植中心共开展肺移植手术500余例。特发性肺间质纤维化、慢性阻塞性肺疾病、继发性肺间质纤维化和尘肺病是中国肺移植受者的主要原发疾病。单肺移植占57.6%,双肺移植占42.4%。双肺移植围手术期(<30天)、1年、3年生存率分别为78.5%、64.5%、48.9%。单肺移植受者相应存活率分别为83.0%、69.9%和46.8%。武汉大学人民医院于2020年完成湖北省首例新冠肺炎肺移植手术,术后患者均顺利康复出院。虽然中国在肺移植方面取得了很大的进步,但仍需要认识到,多学科团队合作模式和数据注册管理仍需进一步加强,以便提供更多的临床指南和专家共识,使各肺移植中心稳步发展和完善。中国的肺移植将逐步提升到世界器官移植舞台的中心。©2021,武汉大学医学杂志编辑委员会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。